Speckle-type POZ protein as a diagnostic biomarker in renal cell carcinoma
Authors:
- 1 July 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cancer Research and Therapeutics
- Vol. 14 (5) , 977-982
Abstract
Background: Renal cell carcinoma (RCC) is the most common kidney neoplasm and requires an early diagnosis because of poor response to conventional cancer treatments. However, till date, there is no reliable tumor marker available for the diagnosis of RCC. Objective: The aim of the study was to evaluate the expression of speckle-type POZ protein (SPOP) as a biomarker in patients with RCC. Materials and Methods: Blood samples were collected from fifty patients with RCC and ten healthy controls. Tumor tissue samples were obtained from nephrectomy specimen. Adjoining normal renal parenchyma of these fifty patients and eight normal renal tissue samples from normal kidney served as controls. Reverse transcriptase-polymerase chain reaction assay was performed for SPOP and mammalian target of rapamycin expression. Results: SPOP was significantly increased in blood of patients with RCC as compared to controls (0.754 ± 0.32 vs. 0.224 ± 0.14; P < 0.001). Twenty-two patients (44%) had SPOP value more than mean + 2 standard deviation (SD) of controls. In RCC tissue, 42 (84%) patients had increased expression of SPOP more than 0.523 (mean + 2 SD value of SPOP expression in controls). SPOP expression was high in blood of 60% patients and in tumor tissue of 90% patients with clear cell RCC. SPOP was higher in high grade and high stage of RCC. Conclusions: Our result suggests that SPOP expression in blood might have a sensitivity that is low for routine diagnostic use and for screening for RCC. However, SPOP could be a potential tissue diagnostic biomarker in RCC.Keywords
This publication has 20 references indexed in Scilit:
- Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management StrategiesJNCI: Journal of the National Cancer Institute, 2012
- A Gene Expression Signature from Peripheral Whole Blood for Stage I Lung AdenocarcinomaCancer Prevention Research, 2011
- Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1Oncogene, 2011
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Renal Cell Carcinoma Correlates with PrognosisCancer Epidemiology, Biomarkers & Prevention, 2009
- Treatment of kidney cancerCancer, 2009
- Analysis of Drosophila Segmentation Network Identifies a JNK Pathway Factor Overexpressed in Kidney CancerScience, 2009
- Individualized Medicine for Renal Cell Carcinoma: Establishment of Primary Cell Line Culture from Surgical SpecimensJournal of Endourology, 2008
- Identification of Nicotinamide N-Methyltransferase as a Novel Tumor Marker for Renal Clear Cell CarcinomaJournal of Urology, 2006
- Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast CancersClinical Cancer Research, 2004